<DOC>
	<DOCNO>NCT00019123</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may kill cancer cell stop growth new blood vessel tumor . PURPOSE : Phase II trial study effectiveness thalidomide treat patient HIV-associated Kaposi 's sarcoma .</brief_summary>
	<brief_title>Thalidomide Treating Patients With HIV-Associated Kaposi 's Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antitumor activity thalidomide term regression stabilization disease patient HIV-associated Kaposi 's sarcoma . II . Determine toxic effect regimen patient . III . Determine pharmacokinetics regimen patient . OUTLINE : Patients receive oral thalidomide day 1 . Treatment continue daily 6 month absence disease progression unacceptable toxicity . Patients complete partial response stable disease 6 month treatment may continue treatment additional 6 month . Patients follow 1 , 6 , 12 month . PROJECTED ACCRUAL : A total 15-25 evaluable patient accrue study within 3.75-6.25 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove Kaposi 's sarcoma ( KS ) HIVpositive ELISA Western blot Disease progression within past 2 month Evaluable disease noninvasive method Minimum 5 measurable lesion previously untreated local therapy ( intralesional injection ) Ineligible reduce performance status beyond minimally symptomatic pulmonary disease potentially acutely lifethreatening KS present Visceral disease , include pulmonary disease , allow follow condition meet : Not acutely lifethreatening No effect performance status beyond minimal symptom No urgent requirement chemotherapy May ineligible actively bleed critically locate KS lesion present pose immediate risk PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : More 3 month Hematopoietic : Absolute neutrophil count least 750/mm3 Platelet count least 70,000/mm3 Hemoglobin least 8 g/dL ( least 1 month since prior transfusion ) Hepatic : Bilirubin great 2.0 mg/dL ( great 3.8 mg/dL elevation due protease inhibitor Gilbert 's syndrome ) AST ALT great 125 U/L PT APTT great 120 % control No history hepatic cirrhosis Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 70 mL/min Pulmonary : See Disease Characteristics Other : Not pregnant Negative pregnancy test Fertile patient must use effective hormonal barrier contraception least 1 week , , least 1 month study No great grade 1 peripheral neuropathy etiology except localize neuropathy due mechanical cause trauma No malignancy within past year except completely resect basal cell skin cancer No grade 3 toxicity except lymphopenia neutropenia No hypersensitivity thalidomide related compound No evidence underlie severe lifethreatening bacterial , viral , fungal , protozoal infection within past 2 week Fever 39 degree Celsius great within past 10 day allow due severe underlie infection PRIOR CONCURRENT THERAPY : Biologic therapy : No prior interferon No prior thalidomide KS At least 6 month since prior suramin Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : No prior systemic steroid except physiologic replacement dos corticosteroid , sex hormone , noncorticosteroids anabolic steroid waste syndrome Concurrent shortterm course steroids allow Radiotherapy : No prior radiotherapy Surgery : Not specify Other : At least 2 week since prior antiretroviral therapy OR On stable dos 1 follow least 2 week study : Zidovudine , zalcitabine , didanosine , lamivudine , stavudine Protease inhibitor Nonnucleoside reverse transcriptase inhibitor No prior systemic antiKS agent regimen No concurrent antiKS therapy first 6 month study No concurrent sedate drug reduce minimal level , sedate recreational drug , alcohol No change , initiation , discontinuation antiretroviral therapy unless medically indicate Concurrent intralesional therapy 6 month study rare occasion occasional painful disfigure lesion allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>AIDS-related Kaposi sarcoma</keyword>
</DOC>